We monitored the individual tumor’s response to anti-PD-L1 IgG for 7 days and correlate the tumor size change with the amount of fluorescently labeled anti-PD-L1 IgG specifically delivered to each tumor (Figure 3). This evidence concerns the gene CD274 and neoplasm.